Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET

Company Participants

Kate Rausch - Head, Investor Relations

Paul Bolno - President and Chief Executive Officer

Mike Panzara - Chief Medical Officer, Head, Therapeutics Discovery and Development

Kyle Moran - Chief Financial Officer

Conference Call Participants

Joon Lee - Truist Securities

Salim Syed - Mizuho

Lisa Walter - RBC

Alex Thompson - Stifel

Mani Foroohar - SVB Securities

Suji Jeong - Jefferies

Operator

Good morning and welcome to the Wave Life Sciences First Quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast.

I will now turn the call over to Kate Rausch, VP of Investor Relations and Corporate Affairs at Wave Life Sciences. Please go ahead.

Kate Rausch

Good morning, and thank you for joining us today to discuss our recent business progress and review Wave’s first quarter 2022 financial results. Joining me today with prepared remarks are Dr. Paul Bolno, Wave’s President and Chief Executive Officer; Dr. Mike Panzara, Chief Medical Officer, Head of Therapeutics Discovery and Development; and Kyle Moran, Chief Financial Officer.

The press release issued this morning and the slide presentation to accompany this webcast are available in the Investors section of our website www.wavelifesciences.com.

Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to a several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2021 and our quarterly report on Form 10-Q for the quarter ended March 31, 2022. We undertake no obligation to update or revise any forward-looking statement for any reason.

I would now like to turn the call over to Paul. Paul?

Paul Bolno

Thanks, Kate. Good morning and thank you all for joining us. Today, I will start by highlighting our achievements so far this year and provide a business update. Mike will discuss our therapeutic pipeline; and finally, Kyle will discuss our first quarter financials.

This has been an exciting first half of 2022 for Wave. We are executing on multiple pillars to drive value for both our shareholders and the patients and families we serve. We remain on track to deliver data from our three clinical programs to rapidly inform their next stages of development. This was exemplified by our recent positive data announcement on our C9 program. Rapidly advance our first RNA editing AIMer Alpha-1 antitrypsin AATD program into IND-enabling toxicology studies, a key step on the path to the clinic and leverage partnership to unlock value from our platform, pipeline to manufacturing.